Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024.
宾夕法尼亚州拉德诺，2024年5月2日（GLOBE NEWSWIRE）——专注于开发针对高血压、慢性肾脏病（CKD）和其他由醛固酮失控引起的疾病的药物的临床阶段生物制药公司Mineralys Therapeutics, Inc.（纳斯达克股票代码：MLYS）今天宣布，将在周四金融市场开盘前公布截至2024年3月31日的第一季度财务业绩，2024 年 5 月 9 日。
| Thursday, May 9th @ 8:30 a.m. ET | |
| Domestic: | 1-888-886-7786 |
| International: | 1-416-764-8658 |
| Conference ID: | 93715931 |
| Webcast: | Link |
| 5月9日，星期四第四 @ 美国东部时间上午 8:30 | |
| 国内： | 1-888-886-7786 |
| 国际： | 1-416-764-8658 |
| 会议编号： | 93715931 |
| 网络直播： | 链接 |
Participants can use the dial-in information above or choose the Call me option (click here) for instant telephone access to the event which will be made active 15 minutes prior to the scheduled start time. A live webcast of the conference call may be found here or on the "News & Events" page in the Investor Relations section of the Mineralys Therapeutics website.
参与者可以使用上面的拨入信息，也可以选择 “给我打电话” 选项（单击此处）以即时电话访问活动，活动将在预定开始时间前 15 分钟激活。可以在此处或Mineralys Therapeutics网站投资者关系部分的 “新闻与活动” 页面上找到电话会议的网络直播。
About Mineralys Therapeutics
关于 Mineralys 疗法
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit Follow Mineralys on LinkedIn and Twitter.
Mineralys Therapeutics是一家临床阶段的生物制药公司，专注于开发针对高血压、慢性肾病和其他由醛固酮失调引起的疾病的药物。其最初的候选产品lorundrostat是一种专有的、口服给药的高选择性醛固酮合酶抑制剂，Mineralys Therapeutics正在开发该抑制剂，用于受醛固酮失调影响的心肾疾病，包括高血压和慢性肾病。Mineralys总部位于宾夕法尼亚州的拉德诺，由Catalys Pacific创立。欲了解更多信息，请访问领英和推特上关注Mineralys。
Contact:
Investor Relations
investorrelations@mineralystx.com
联系人：
投资者关系
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
媒体关系
汤姆·韦布尔
Elixir Health 公共关系
电话：(1) 515-707-9678
电子邮件：tweible@elixirhealthpr.com
译文内容由第三方软件翻译。